Effect of rechallenge nivolumab in a hemodialysis patient with multiple metastases from a rapidly progressed T1a renal clear cell carcinoma: An autopsy case

被引：0

作者：

Hanawa, Kazushi ^{[1
]}

Sawada, Norifumi ^{[1
]}

Yokota, Yuka ^{[2
]}

Aikawa, Junki ^{[1
]}

Otake, Yuko ^{[1
]}

Sugimura, Koki ^{[1
]}

Shimura, Hiroshi ^{[1
]}

Mochizuki, Takanori ^{[1
]}

Kira, Satoru ^{[1
]}

Mitsui, Takahiko ^{[1
]}

机构：

[1] Univ Yamanashi, Interdisciplinary Grad Sch Med, Dept Urol, Shimokato 1110, Chuo City, Yamanashi 4093898, Japan

[2] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Human Pathol, Chuo City, Yamanashi, Japan

来源：

IJU CASE REPORTS | 2024年 / 7卷 / 03期

关键词：

autopsy; hemodialysis; metastasis; nivolumab; T1a renal cell carcinoma; DIALYSIS; OUTCOMES; DISEASE; SAFETY;

D O I：

10.1002/iju5.12699

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

IntroductionDistant metastasis of T1a renal cell carcinoma is rare and whether metastasis is more probable in patients undergoing hemodialysis remains unclear. We report the autopsy case of a patient undergoing hemodialysis with multiple metastases that rapidly progressed from T1a renal cell carcinoma treated with multimodal therapy including nivolumab.Case presentationA 70-year-old male who underwent hemodialysis was diagnosed with clear cell carcinoma (pT1a, G2) after nephrectomy. Six months post-surgery, bone and lung metastases appeared and treated with radiotherapy and pazopanib, respectively. Nivolumab was administered as second- and fourth-line treatments for lung metastases. The patient died approximately 60 months after initial diagnosis; however, nivolumab controlled disease progression for 24 months. An autopsy revealed the lung's occupation with clear cell carcinoma tumor tissue.ConclusionNivolumab has potential to control lung metastasis progression. Additionally, rechallenge is possible in patients with renal cell carcinoma undergoing hemodialysis.

引用

页码：202 / 205

页数：4

共 21 条

[21] Multiple Brain Metastases in a Patient with ROS1 Fusion-Positive Lung Adenocarcinoma as a Disease Flare due to Crizotinib Cessation Caused by Disseminated Aseptic Inflammation from Crizotinib-Associated Renal Cysts: A Case Report [J].

Amano, Yosuke ;

Kage, Hidenori ;

Tanaka, Goh ;

Sato, Yusuke ;

Tanaka, Mariko ;

Nagase, Takahide .

CASE REPORTS IN ONCOLOGY, 2022, 15 (01) :338-344

← 1 2 3 →